JP5566466B2 - カバジタキセルの新規の抗腫瘍的使用 - Google Patents

カバジタキセルの新規の抗腫瘍的使用 Download PDF

Info

Publication number
JP5566466B2
JP5566466B2 JP2012535996A JP2012535996A JP5566466B2 JP 5566466 B2 JP5566466 B2 JP 5566466B2 JP 2012535996 A JP2012535996 A JP 2012535996A JP 2012535996 A JP2012535996 A JP 2012535996A JP 5566466 B2 JP5566466 B2 JP 5566466B2
Authority
JP
Japan
Prior art keywords
prostate cancer
cabazitaxel
pharmaceutical composition
administered
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012535996A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013509394A (ja
JP2013509394A5 (https=
Inventor
グプタ，スニル
Original Assignee
アバンテイス・フアルマ・エス・アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43567614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5566466(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アバンテイス・フアルマ・エス・アー filed Critical アバンテイス・フアルマ・エス・アー
Publication of JP2013509394A publication Critical patent/JP2013509394A/ja
Publication of JP2013509394A5 publication Critical patent/JP2013509394A5/ja
Application granted granted Critical
Publication of JP5566466B2 publication Critical patent/JP5566466B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
JP2012535996A 2009-10-29 2010-10-27 カバジタキセルの新規の抗腫瘍的使用 Active JP5566466B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US25616009P 2009-10-29 2009-10-29
US61/256,160 2009-10-29
US29390310P 2010-01-11 2010-01-11
US61/293,903 2010-01-11
US35588810P 2010-06-17 2010-06-17
US35583410P 2010-06-17 2010-06-17
US61/355,834 2010-06-17
US61/355,888 2010-06-17
US36992910P 2010-08-02 2010-08-02
US61/369,929 2010-08-02
US38393310P 2010-09-17 2010-09-17
US61/383,933 2010-09-17
US38996910P 2010-10-05 2010-10-05
US61/389,969 2010-10-05
PCT/IB2010/054866 WO2011051894A1 (en) 2009-10-29 2010-10-27 Novel antitumoral use of cabazitaxel

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014123108A Division JP6182510B2 (ja) 2009-10-29 2014-06-16 カバジタキセルの新規の抗腫瘍的使用

Publications (3)

Publication Number Publication Date
JP2013509394A JP2013509394A (ja) 2013-03-14
JP2013509394A5 JP2013509394A5 (https=) 2013-10-10
JP5566466B2 true JP5566466B2 (ja) 2014-08-06

Family

ID=43567614

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012535996A Active JP5566466B2 (ja) 2009-10-29 2010-10-27 カバジタキセルの新規の抗腫瘍的使用
JP2014123108A Active JP6182510B2 (ja) 2009-10-29 2014-06-16 カバジタキセルの新規の抗腫瘍的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014123108A Active JP6182510B2 (ja) 2009-10-29 2014-06-16 カバジタキセルの新規の抗腫瘍的使用

Country Status (31)

Country Link
US (8) US8927592B2 (https=)
EP (1) EP2493466B1 (https=)
JP (2) JP5566466B2 (https=)
KR (1) KR101712231B1 (https=)
CN (1) CN102770131A (https=)
AR (1) AR078824A1 (https=)
AU (4) AU2010310986A1 (https=)
BR (1) BR112012011457A2 (https=)
CA (1) CA2779009A1 (https=)
CR (1) CR20120204A (https=)
DK (1) DK2493466T3 (https=)
EA (1) EA024186B1 (https=)
EC (1) ECSP12011836A (https=)
ES (1) ES2862340T3 (https=)
GT (1) GT201200123A (https=)
IL (3) IL219443A0 (https=)
MA (1) MA33767B1 (https=)
MX (1) MX336339B (https=)
MY (1) MY164086A (https=)
NI (1) NI201200071A (https=)
PE (1) PE20121429A1 (https=)
PH (1) PH12012500848A1 (https=)
PL (1) PL2493466T3 (https=)
PT (1) PT2493466T (https=)
SG (1) SG10201810928SA (https=)
SV (1) SV2012004192A (https=)
TN (1) TN2012000188A1 (https=)
TW (2) TWI533866B (https=)
UY (1) UY32987A (https=)
WO (1) WO2011051894A1 (https=)
ZA (1) ZA201203123B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
CN102770131A (zh) 2009-10-29 2012-11-07 安万特医药股份有限公司 卡巴他赛的新颖抗肿瘤用途
JP2014514306A (ja) * 2011-04-12 2014-06-19 プラス・ケミカルス・エスアー 固体形態のカバジタキセル及びその製造方法
CN102503913B (zh) * 2011-10-20 2014-03-26 江苏红豆杉生物科技股份有限公司 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法
JP6025861B2 (ja) * 2011-12-13 2016-11-16 アベンティス・ファーマ・ソシエテ・アノニム カバジタキセルの結晶形およびこれを調製するための方法
WO2013111157A1 (en) * 2012-01-03 2013-08-01 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
CN104583189A (zh) 2012-07-31 2015-04-29 永信药品工业股份有限公司 非晶型的卡巴利他索
TW201438714A (zh) * 2013-03-04 2014-10-16 Aventis Pharma Sa 卡巴他賽（ｃａｂａｚｉｔａｘｅｌ）及其治療轉移性前列腺癌之用途
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
PT3258931T (pt) * 2015-02-17 2020-09-23 Univ Erasmus Med Ct Rotterdam Utilização do cabazitaxel no tratamento do cancro da próstata
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
EP3509569A1 (en) 2016-09-07 2019-07-17 Cadila Healthcare Limited Sterile injectable compositions comprising drug micelles
US10195214B2 (en) 2017-03-01 2019-02-05 Corcept Therapeutics, Inc. Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
US20210088505A1 (en) * 2017-04-07 2021-03-25 La Jolla Institute For Allergy And Immunology Unipotent Neutrophil Progenitor Cells, Methods of Preparation, and Uses Thereof
US20250017891A1 (en) * 2023-07-04 2025-01-16 Twi Pharmaceuticals, Inc. Pharmaceutical composition comprising cabazitaxel prodrug-cyclodextrin inclusion complex, and applications thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5005588A (en) 1989-10-13 1991-04-09 David Rubin Method for increasing tumor sensitivity to chemotherapy
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
ZA94128B (en) 1993-02-01 1994-08-19 Univ New York State Res Found Process for the preparation of taxane derivatives and betalactam intermediates therefor
FR2732340B1 (fr) 1995-03-27 1997-04-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
US5847170A (en) 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
US6372780B2 (en) 1995-03-27 2002-04-16 Aventis Pharma S.A. Methods of treating cell lines expressing multidrug resistance P-glycoprotein
FR2745814B1 (fr) 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
US6346543B1 (en) 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
WO2000010547A2 (en) 1998-08-20 2000-03-02 Aventis Pharma S.A. New use of taxoid derivatives
US6403634B1 (en) 1999-01-13 2002-06-11 Aventis Pharma S.A. Use of taxoid derivatives
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
SI1493556T1 (sl) 2003-07-02 2006-02-28 Scheuten Glasgroep Bv Postopek za pripravo protipozarne zasteklitve
EP1498120A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
SG156625A1 (en) 2004-12-08 2009-11-26 Aventis Pharma Inc Method for measuring resistance or sensitivity to docetaxel
EP1700596A1 (en) 2005-03-09 2006-09-13 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
FR2922107B1 (fr) 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
EP2177630A1 (en) * 2008-10-02 2010-04-21 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
CN103932972A (zh) 2009-03-30 2014-07-23 天蓝制药公司 聚合物-药剂缀合物、颗粒、组合物和相关使用方法
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
US20110160159A1 (en) 2009-09-15 2011-06-30 John Ryan Treatment of cancer
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
CN102770131A (zh) 2009-10-29 2012-11-07 安万特医药股份有限公司 卡巴他赛的新颖抗肿瘤用途
ES2621613T3 (es) 2009-11-04 2017-07-04 Emcure Pharmaceuticals Limited Un proceso mejorado para la preparación de derivados de taxano
AU2010321533A1 (en) 2009-11-23 2012-05-31 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2011124669A1 (en) 2010-04-08 2011-10-13 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
WO2011130317A2 (en) 2010-04-13 2011-10-20 Amplyx Pharmaceuticals Inc. Therapeutic agents having reduced toxicity
AU2011239569B2 (en) 2010-04-16 2014-07-24 Baylor College Of Medicine Method for treating solid tumors
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Also Published As

Publication number Publication date
US20190151278A1 (en) 2019-05-23
US20200155497A1 (en) 2020-05-21
MX2012005030A (es) 2012-12-05
PT2493466T (pt) 2021-03-29
SV2012004192A (es) 2012-08-23
US8927592B2 (en) 2015-01-06
TWI533866B (zh) 2016-05-21
AR078824A1 (es) 2011-12-07
MY164086A (en) 2017-11-30
JP2014196323A (ja) 2014-10-16
JP6182510B2 (ja) 2017-08-16
KR20120093986A (ko) 2012-08-23
NI201200071A (es) 2012-08-20
DK2493466T3 (da) 2021-04-26
CA2779009A1 (en) 2011-05-05
TWI654975B (zh) 2019-04-01
EP2493466B1 (en) 2021-03-10
SG10201810928SA (en) 2019-01-30
US12453712B2 (en) 2025-10-28
AU2019203514A1 (en) 2019-06-06
US20210169843A1 (en) 2021-06-10
US20150118182A1 (en) 2015-04-30
PE20121429A1 (es) 2012-11-06
EP2493466A1 (en) 2012-09-05
US10583110B2 (en) 2020-03-10
AU2010310986A1 (en) 2012-06-14
PH12012500848A1 (en) 2016-02-08
IL267583A (en) 2019-08-29
TW201611831A (en) 2016-04-01
TN2012000188A1 (en) 2013-12-12
CN102770131A (zh) 2012-11-07
ES2862340T3 (es) 2021-10-07
EA024186B1 (ru) 2016-08-31
AU2016200598A1 (en) 2016-02-25
ZA201203123B (en) 2013-06-26
PL2493466T3 (pl) 2021-11-15
MX336339B (es) 2016-01-14
BR112012011457A2 (pt) 2016-05-03
UY32987A (es) 2011-05-31
KR101712231B1 (ko) 2017-03-03
CR20120204A (es) 2012-07-04
IL219443A0 (en) 2012-06-28
IL250254A0 (en) 2017-03-30
US20150104411A1 (en) 2015-04-16
EA201270606A1 (ru) 2013-01-30
ECSP12011836A (es) 2012-07-31
AU2017232227B2 (en) 2019-06-06
US20120301425A1 (en) 2012-11-29
TW201127374A (en) 2011-08-16
US10716777B2 (en) 2020-07-21
AU2017232227A1 (en) 2017-10-12
WO2011051894A1 (en) 2011-05-05
US20180125810A1 (en) 2018-05-10
JP2013509394A (ja) 2013-03-14
US20240139146A1 (en) 2024-05-02
MA33767B1 (fr) 2012-11-01
GT201200123A (es) 2013-11-07

Similar Documents

Publication Publication Date Title
JP6182510B2 (ja) カバジタキセルの新規の抗腫瘍的使用
KR20160078987A (ko) 플리나불린 및 탁산의 조합에 의한 암 치료
AU2015200149B2 (en) Novel antitumoral use of cabazitaxel
CN108135878A (zh) 卡巴他赛及其治疗癌症的用途
HK1173071B (en) Novel antitumoral use of cabazitaxel
HK1173071A (en) Novel antitumoral use of cabazitaxel
CN1988904A (zh) 埃坡霉素组合
CA2708489A1 (en) Use of cabazitaxel and a prednisone or a prednisolone in the treatment of prostate cancer
EP3797834A1 (en) Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent
WO2024105049A1 (en) Lurbinectedin and doxorubicin combination
UA110606C2 (uk) Нове протипухлинне застосування кабазитакселу
Holle et al. Overview of Cancer Therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130820

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20130820

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20130912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140418

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140520

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140617

R150 Certificate of patent or registration of utility model

Ref document number: 5566466

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250